PMID- 29502374
OWN - NLM
STAT- MEDLINE
DCOM- 20180313
LR  - 20190221
IS  - 0253-3766 (Print)
IS  - 0253-3766 (Linking)
VI  - 40
IP  - 2
DP  - 2018 Feb 23
TI  - [A randomized controlled study of erlotinib versus pemetrexed combined with 
      cisplatin in neoadjuvant therapy of stage ⅢA EGFR-mutant lung adenocarcinoma].
PG  - 133-137
LID - 10.3760/cma.j.issn.0253-3766.2018.02.010 [doi]
AB  - Objective: To evaluate the feasibility, efficacy and safety of epidermal growth 
      factor receptor-tyrosine kinase inhibitors(EGFR-TKIs) for neoadjuvant therapy. 
      Methods: Eighty-six patients with stage ⅢA EGFR-mutant lung adenocarcinoma were 
      assigned to 2 groups (n=43 in each group) according to the random number table 
      method: neoadjuvant targeted therapy group (single oral dose of erlotinib 150 mg 
      per day, for 9 weeks) and neoadjuvant chemotherapy group (2 cycles of pemetrexed 
      combined with cisplatin chemotherapy followed by 3- week discontinuation). 
      Surgical treatment was underwent after imaging efficacy evaluation. Results: In 
      neoadjuvant targeted therapy group, 4 achieved complete response (CR), 25 
      achieved partial response (PR), giving an objective response rate (ORR) of 67.4%. 
      In pathological response, 8 patients had grade Ⅰ, 20 patients had grade Ⅱ, giving 
      a pathological response rate of 65.1%. The most frequent adverse events (AEs) 
      were rash and diarrhea. In neoadjuvant chemotherapy group, 2 had CR and 17 had 
      PR, giving an ORR of 44.2%. In pathological response, 3 patients had grade Ⅰ, 15 
      patients had grade Ⅱ, giving a pathological response rate of 41.9%. The main AEs 
      were hematologic toxic effects. The ORR, histological efficacy and hematologic 
      toxicity showed statistical significance between the two groups (P<0.05). The 
      neoadjuvant targeted therapy group had 90.7% resection rate, (299.8+/-23.4) ml of 
      hemorrhage volume during operation, (5.2+/-0.4) days of extubation time and 9.3% 
      postoperative complication rate. Corresponding results were 83.7%, (308.9+/-22.7) 
      ml, (5.4+/-0.6) days and 11.6% in neoadjuvant chemotherapy group, which showed no 
      statistical significance (P>0.05). Conclusions: Neoadjuvant targeted treatment 
      for stage ⅢA lung adenocarcinoma harboring EGFR mutations. The regimen could be 
      considered as a choice of neoadjuvant treatment for patients with stage ⅢA 
      EGFR-mutant lung adenocarcinoma.
FAU - Chen, W Q
AU  - Chen WQ
AD  - Department of Thoracic Oncosurgery-3, Jilin Province Cancer Hospital, Changchun 
      130021, China.
FAU - Li, P
AU  - Li P
AD  - Department of Thoracic Oncosurgery-3, Jilin Province Cancer Hospital, Changchun 
      130021, China.
FAU - Wang, Q
AU  - Wang Q
AD  - Department of Thoracic Oncosurgery-3, Jilin Province Cancer Hospital, Changchun 
      130021, China.
FAU - Zhang, Y J
AU  - Zhang YJ
AD  - Department of Thoracic Oncosurgery-3, Jilin Province Cancer Hospital, Changchun 
      130021, China.
FAU - Li, H Y
AU  - Li HY
AD  - Department of Thoracic Oncosurgery-3, Jilin Province Cancer Hospital, Changchun 
      130021, China.
FAU - Jin, X T
AU  - Jin XT
AD  - Department of Thoracic Oncosurgery-3, Jilin Province Cancer Hospital, Changchun 
      130021, China.
FAU - Yan, S
AU  - Yan S
AD  - Department of Thoracic Oncosurgery-3, Jilin Province Cancer Hospital, Changchun 
      130021, China.
FAU - Kou, G F
AU  - Kou GF
AD  - Department of Thoracic Oncosurgery-3, Jilin Province Cancer Hospital, Changchun 
      130021, China.
FAU - Cai, S L
AU  - Cai SL
AD  - Department of Thoracic Oncosurgery-3, Jilin Province Cancer Hospital, Changchun 
      130021, China.
FAU - Liu, G
AU  - Liu G
AD  - Department of Thoracic Oncosurgery-3, Jilin Province Cancer Hospital, Changchun 
      130021, China.
LA  - chi
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - China
TA  - Zhonghua Zhong Liu Za Zhi
JT  - Zhonghua zhong liu za zhi [Chinese journal of oncology]
JID - 7910681
RN  - 0 (Protein Kinase Inhibitors)
RN  - 04Q9AIZ7NO (Pemetrexed)
RN  - DA87705X9K (Erlotinib Hydrochloride)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Adenocarcinoma/*drug therapy/genetics/pathology
MH  - Adenocarcinoma of Lung
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Cisplatin/administration & dosage
MH  - ErbB Receptors/*antagonists & inhibitors/genetics
MH  - Erlotinib Hydrochloride/administration & dosage
MH  - Feasibility Studies
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/genetics/pathology
MH  - Mutation
MH  - Neoadjuvant Therapy
MH  - Pemetrexed/administration & dosage
MH  - Protein Kinase Inhibitors/*therapeutic use
OTO - NOTNLM
OT  - Adenocarcinoma
OT  - Epidermal growth factor receptor
OT  - Lung neoplasms
OT  - Molecular targeted therapy
OT  - Neoadjuvant therapy
EDAT- 2018/03/06 06:00
MHDA- 2018/03/14 06:00
CRDT- 2018/03/06 06:00
PHST- 2018/03/06 06:00 [entrez]
PHST- 2018/03/06 06:00 [pubmed]
PHST- 2018/03/14 06:00 [medline]
AID - 10.3760/cma.j.issn.0253-3766.2018.02.010 [doi]
PST - ppublish
SO  - Zhonghua Zhong Liu Za Zhi. 2018 Feb 23;40(2):133-137. doi: 
      10.3760/cma.j.issn.0253-3766.2018.02.010.